Short-term cost cutting is not the answer.
Evans
Marc
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics
D047228:Angiotensin II Type 1 Receptor Blockers